# GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

> **NCT03733587** · PHASE1 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** GX-I7
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03733587
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-17
- **Primary completion:** 2020-04-02
- **Final completion:** 2020-05-13
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733587, "GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03733587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*